The burgeoning landscape of novel treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a similar https://nicolasjiqo906418.wikicommunication.com/5836756/retatrutide_vs_tirzepatide_a_comparative_analysis